Systematic Review

Risk of gentamicin toxicity in neonates treated for possible severe bacterial infection in low- and middle-income countries: Systematic Review

Grace M. Musiime¹, Anna C. Seale²,³, Sarah G. Moxon³ and Joy E. Lawn³

¹Gertrude’s Children’s Hospital, Nairobi, Kenya
²Department of Infectious Diseases Informatics, University College London, London, UK
³Centre for Maternal, Adolescent, Reproductive and Child Health (MARCH), and Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

Abstract

OBJECTIVES  To assess the risk of gentamicin toxicity and potential number of neonates exposed annually to this risk, through treatment with WHO-recommended first-line antibiotics (gentamicin with penicillin) for the 6.9 million neonates with possible serious bacterial infection (PSBI).
METHODS  Systematic literature review and assessment of the evidence using Cochrane and GRADE criteria. Meta-analysis was undertaken for pooled estimates where appropriate.
RESULTS  Eleven studies (946 neonates) were included (nine randomised controlled trials and two prospective cohort studies). Six trials reported consistently measured ototoxicity outcomes in neonates treated with gentamicin, and the pooled estimate for hearing loss was 3% (95% CI 0–7%). Nephrotoxicity could not be assessed due to variation in case definitions used. Estimates of the number of neonates potentially affected by gentamicin toxicity were not undertaken due to insufficient data.
CONCLUSION  Given wider scale-up of outpatient-based and lower-level treatment of PSBI, improved data are essential to better assess the risks from neonatal gentamicin treatment without assessment of blood levels, to maximise benefit and reduce harm.

keywords  gentamicin, toxicity, neonates, sepsis, bacterial infection, systematic review

Introduction

Neonatal infections account for an estimated 580 000 newborn deaths globally each year (2012), with the greatest burden in low- and middle-income countries (LMICs) [1]. Cases of neonatal possible serious bacterial infection (PSBI) in 2012 were estimated at 6.9 million (uncertainty range 5.5–8.3 million), in neonates over 32 weeks gestation (or >1500 g) in South Asia (SA), sub-Saharan Africa (sSA) and Latin America and the Caribbean (LAC) [2]. These neonates are assessed for treatment using sensitive but non-specific clinical criteria, as described in the World Health Organization’s (WHO) Integrated Management of Childhood Illness (IMCI) programme [3, 4].

Current WHO guidelines recommend gentamicin with ampicillin or penicillin as first-line therapy for all cases of neonatal sepsis [5]. The United Nations Commission on Life Saving Commodities (UNCoLSC) [6] has listed parenteral antibiotics for newborns’ infections as a priority, and investment is increasing for scaling-up of treatment including at lower levels of the health system. Recently published multicountry studies suggest that simplified antibiotic regimes, still including gentamicin, could be administered on an outpatient basis where referral was not possible, and WHO have changed their guidelines to reflect this, although concerns have been raised about the sample size required for true equivalence [7, 8]. Some countries with poor access to facility-based care are already scaling-up community-based management of neonatal PSBI; for example, Ethiopia is in process of national scale-up, using Health Extension Workers [9].

Gentamicin is an aminoglycoside antibiotic widely used due to its efficacy, low cost and availability [10]. However, it has the potential for toxicity, particularly ototoxicity and nephrotoxicity [11–13]. In adults,
ototoxicity is irreversible affecting both cochlear and vestibular systems, but gentamicin is predominantly vestibulotoxic [14–17]. Studies of gentamicin-associated toxicity are difficult in neonates, as hearing loss and renal impairment after severe bacterial infection are often multifactorial in origin (Figure 1). Sepsis, poor feeding and asphyxia commonly cause acute kidney injury (AKI), and hearing impairment can follow neonatal meningitis and tetanus [18–20, 21]. Other factors associated with infection, such as hypoxia and hyperbilirubinaemia, are also associated with hearing loss [17, 20, 22–24].

Due to concerns about potential toxicity, in well-resourced settings, therapeutic drug monitoring (serum levels) is used to reduce the likelihood of toxicity. Trough levels >2 μg/ml and peak levels >10 μg/ml are associated with increased risk [12, 25, 26], but these ranges have been extrapolated from adult literature and their appropriateness is not completely clear [27, 28]. Neonatal toxicity risk is likely increased by repeat courses, exposure to trough concentrations >2 μg/ml for more than 10 days and baseline renal impairment [29]. Genetic factors also influence susceptibility to gentamicin ototoxicity [30–32].
The high case fatality risk of neonatal PSBI in LMICs demands that neonatal PSBI cases are treated and delays avoided to reduce neonatal mortality. However, as case management is scaled-up, including outside of hospital care, it is important to consider the risks of treatment, especially when drug levels are unmonitored. Over-treatment of neonatal PSBI may lead to toxicity even amongst neonates who do not have true bacterial infection, and this review focuses on assessing the risk of gentamicin toxicity in neonates.

We aimed to assess risks of gentamicin toxicity in neonates, through systematic literature review and meta-analysis, to enable estimation of the number of neonates at risk of gentamicin toxicity, given recent estimates of 6.9 million neonates in South Asia, Latin America and sub-Saharan Africa needing treatment [2].

**Methods**

**Searches**

The following databases were searched without date or language restrictions to identify published data on risks of gentamicin toxicity in neonates and risk of exposure to inaccurate dosing; MEDLINE, EMBASE, Cochrane Libraries and WHO regional databases (Lilacs, EMRO, AFRO, Figure 2). The ‘human’ limit was applied on MEDLINE and EMBASE. Combinations of the following terms were used as follows: ‘gentamicin’, ‘neonate’, ‘toxicity’ and ‘dosing error’. Medical subject heading terms were used where available. Searches were last updated on 3 March 2015. Studies potentially fulfilling the predefined inclusion criteria were selected for full text review after initial screening of titles and abstracts. Further literature was identified through snowball searching.

**Inclusion/exclusion criteria and definitions**

The PICO format (population, intervention, comparison, outcomes) was applied as follows. The population of interest was neonates with suspected or proven sepsis or bacterial infection. Neonatal PSBI was defined as any one of the following reported clinical signs or symptoms; temperature of 37.5 °C or more, temperature of 35.5 °C or less, poor feeding, moving only in response to stimulation, significant chest indrawing, increased rate of respiration and history of convulsions. This definition was derived from the Young Infants Clinical Signs Study [33]. Studies which listed suspected or proven sepsis as the indication for treatment without providing a specific case definition were not excluded on this basis as this was not the focus of the review.

The intervention under review was treatment with gentamicin. The comparison was no treatment or use of an alternative antibiotic; however, due to the paucity of data quantifying gentamicin toxicity in neonates, studies comparing different aminoglycosides or gentamicin dosing regimens were also considered.

The outcomes of interest were nephrotoxicity and ototoxicity occurring as a consequence of gentamicin use and exposure to gentamicin dosing errors. Nephrotoxicity was defined as increments in serum creatinine (SCr) levels as per the thresholds specified in each individual study. Studies using serum or urinary biomarkers to quantify nephrotoxicity were not included as they are the subject of research, and studies evaluating these biomarkers used serum creatinine as the gold standard comparison test [34–36]. Ototoxicity was subclassified as auditory and vestibular toxicity. Auditory toxicity was defined as hearing loss or impairment detected by any validated hearing test. Vestibulotoxicity was defined as vestibular dysfunction detected by any validated vestibular function test.

Systematic reviews, randomised controlled trials and observational studies were included. Duplicate reports and studies that did not fulfil the inclusion criteria were excluded. Longitudinal, case-control and cross-sectional studies that did not control for confounding were not included.

**Abstraction and analyses**

Data from all studies fulfilling the inclusion criteria were abstracted onto a standardised form by a single reviewer. The risk of bias in each study was assessed according to Cochrane guidelines [37]. The quality of the body of evidence for each outcome of interest was assessed using GRADE criteria [38] and the available evidence summarised according to each outcome of interest. Meta-analyses were undertaken where appropriate using STATA version 13.0 [39]. Heterogeneity was assessed using the $I^2$ statistic. Random effects models were used if there was sufficient evidence of heterogeneity ($I^2 > 10\%$) [40]. A summary proportion estimate and corresponding 95% confidence intervals (CI) are reported.

**Modelling approach**

A three-step compartmental model (Figure 3) was developed for estimation of the number of neonates annually at risk of gentamicin toxicity following treatment for pSBI in South Asia (SA), sub-Saharan Africa (sSA) and Latin America and the Caribbean (LAC), adapted from previous work on impairment after neonatal infections.
Figure 2 Study selection and results.
However, data were judged to be insufficient to derive formal estimates of the number of neonates annually at risk of gentamicin toxicity.

**Results**

There were 924 articles identified in the systematic literature search, and an additional four articles identified through snowball searching. After initial screening of titles and abstracts, 46 articles were selected for full text review and 11 studies fulfilling the pre-specified inclusion criteria were identified; nine prospective randomised studies [42–50] and two prospective cohort studies [51, 52] (Figure 2). These 11 studies were conducted between 1979 and 2004 in the United States, Thailand, India and Germany.

Intravenous gentamicin was used in 10 studies and one study [44] used intramuscular gentamicin. The pharmacokinetic properties of gentamicin are equivalent for both intravenous and intramuscular routes of administration so this would be unlikely to influence the outcome [29]. Eight studies [42, 43, 45, 47–51] compared different gentamicin dosing regimens, thus both intervention and comparison groups received gentamicin. Hearing assessments were reported in six trials [42–45, 51, 52], and vestibular function was assessed in one study [52]. Ten studies [42–51] measured and reported serum creatinine. No

---

**Figure 3** Outline of parameters required and three-step compartmental model for estimation of the number of neonates annually at risk of gentamicin toxicity in low- and middle-income countries. CFR, case fatality risk; SA, South Asia; sSA, sub-Saharan Africa; LAC, Latin America and the Caribbean; pSBI, possible severe bacterial infection. Figure adapted from Seale *et al.* [21], http://creativecommons.org/licenses/by-nc-sa/3.0/. 

© 2015 John Wiley & Sons Ltd Tropical Medicine and International Health *Volume 20 No 12 pp 1593–1606 December 2015*
data were identified on frequency of dosing errors. The study characteristics and Cochrane risk of bias assessment for each individual trial are summarised in Table 1, and the GRADE quality assessment is detailed in Table 2.

Ototoxicity
Six studies assessed auditory toxicity; devices used for assessment and findings are summarised in Table 2. Three studies reported no hearing impairment in both intervention and comparison groups. [42–44] Three trials reported hearing loss in both intervention and comparison groups [45, 51], and gentamicin was used in both intervention and comparison groups in two of these studies [45, 51]. Only one study assessed vestibular toxicity [52]. Vestibular function was evaluated using the Bárány rotational test; one infant in the intervention (gentamicin) group had vestibular dysfunction at 3 years of age. There was no vestibular dysfunction noted in the comparison groups where gentamicin was not used.

In the meta-analysis of intervention group data (gentamicin therapy in combination with an additional antibiotic) from six studies [42–45, 51, 52], hearing loss after neonatal treatment with gentamicin was estimated to be 3% (95% CI 0–7%), Figure 4). This estimate does not take into account the auditory toxicity events in the comparison groups.

Nephrotoxicity
Nephrotoxicity was assessed in ten studies; case definitions and findings are summarised in Table 2. Five studies [42–45, 48–50] reported no nephrotoxic events in both intervention and comparison groups. One study [43] reported no difference in serum creatinine between intervention and comparison groups, but did not specifically state whether or not renal impairment was noted during the course of treatment. Three studies reported nephrotoxic events in both intervention and comparison groups [44, 46, 51], and gentamicin was used in both intervention and control groups in one of these studies [51]. One study comparing two gentamicin dosing regimens reported a single nephrotoxic event in the comparison group; this infant received concurrent indomethacin [47]. Due to the variations in case definitions, meta-analysis of nephrotoxicity data was not performed.

Estimates of burden of gentamicin toxicity in neonates with PSBI
In 2012, there were an estimated 6.9 million (uncertainty range 5.5–8.3 million) cases of PSBI in LMICs worldwide [2]. The overall case fatality risk for PSBI in LMICs was estimated to be 0.098 (95% CI 0.074–0.122) [2], and the proportion seeking care was estimated to be 59%; the median value obtained from a recent review of care-seeking behaviour in LMICs [53]. However, there were insufficient data on gentamicin toxicity in neonates for modelling, thus estimates of the numbers of neonates annually at risk of gentamicin toxicity in LMICs were not made.

Discussion
This study shows that despite the high burden of neonatal infection needing treatment, and plans to scale-up care, there are insufficient data to assess whether there is potential for harm in terms of toxicity associated with gentamicin treatment. This is of particular concern given the lack of specificity in diagnosing possible serious bacterial infection. The recent Antenatal Corticosteroids Trial (ACT) whereby lower-level workers prescribed steroids for presumed preterm labour, with four of every five women treated then not delivering preterm, and an increase in neonatal mortality, underlines the critical importance of ensuring that the principle of ‘do no harm’ is considered [54]. Innovation is critical to reach the poorest families who are often outside the health system, but as we work to increase access to PSBI treatment for neonates, we must also assess and minimise the potential for harm.

In the data available for hearing loss after gentamicin treatment, 3% (0–7%) of neonates were estimated to be affected. However, the data were limited; there were six studies, three with no events, and the remaining three all had limitations. In the first of these three, there were five auditory toxicity events in control groups not treated with gentamicin, compared to eight in the group treated with gentamicin [52]. In the second, more than half (57%) of the study population had indirect hyperbilirubinaemia which would increase risk of hearing loss [17, 51], and in the third study, all participants were preterm and thus more susceptible to hearing loss associated with PSBI [21, 45]. Despite the evidence that in adults, gentamicin is predominantly vestibulotoxic, only one study reported vestibular testing in infants after treatment with gentamicin. [15–17, 52] This may be, in part, a result of the longer follow-up time required for quantitative vestibular function testing and the complexity of the assessment [55], but it is important that this question is answered.

There were ten studies that considered renal function; however, case definitions of nephrotoxicity were very variable, limiting the extent to which results from different studies could be compared. A standard case definition
| Study ID, design and location | Intervention | Comparison | Outcomes | Risk of bias | Sequence generation | Allocation concealment | Blinding | Incomplete outcome data | Selective reporting |
|------------------------------|--------------|------------|----------|--------------|---------------------|-----------------------|----------|------------------------|------------------|
| **Agarwal G et al. (2002)** [43]† | 4 mg/kg gentamicin every 24 hour + ampicillin (n = 20) | 2.5 mg/kg gentamicin every 12 hour + ampicillin (n = 21) | Nephrotoxicity and ototoxicity | Low risk; computerised generator used | Low risk; sealed envelopes | High risk; no blinding | Low risk; 7% loss to follow-up | Low risk § |
| **Adelman RD et al. (1987)** [46] RCT; USA | 2.5 mg/kg gentamicin 12 or 8 hourly + ampicillin (n = 45) | 75 mg/kg mezlocillin 12, 8 or 6 hourly (n = 45) | Nephrotoxicity | Low risk; computerised generator used | Unclear; insufficient information in publication | High risk; no blinding | High risk; 18% loss to follow-up | Low risk § |
| **Chotigeat U et al. (2001)** [47] RCT; Thailand | 4-5 mg/kg gentamicin once daily (n = 27)† | 2-2.5 mg/kg gentamicin twice daily (n = 27)‡ | Nephrotoxicity | Unclear; insufficient information in publication | Unclear; insufficient information in publication | High risk; no blinding | Low risk; no loss to follow-up | Low risk § |
| **Finizzi-Hieber T et al. (1979)** [52]† | 5-6 mg/kg/day gentamicin (n = 116)† | 15 mg/kg/day kanamycin (n = 118)† or no therapy (n = 113) | Ototoxicity | Low risk; table of randomised drug regimens used | High risk; no concealment | High risk; no blinding | High risk; 75% loss to follow-up at 4 years | Low risk § |
| **Itsarayoungyen S et al. (1982)** [44]† RCT; USA | 2.5 mg/kg gentamicin 12 hourly + penicillin/ampicillin/methicillin (n = 35) | 2.5 mg/kg tobramycin 12 hourly + penicillin/ampicillin/methicillin (n = 26) | Nephrotoxicity and ototoxicity | Low risk; random numbers table used | Unclear; insufficient information in publication | Low risk; double blinded | High risk; 18% loss to follow-up | Low risk § |
| **Kosalaraksa P et al. (2004)** [48] RCT; Thailand | 5 mg/kg gentamicin 24 hourly + penicillin/ampicillin/cloxacillin (n = 33) | 2.5 mg/kg gentamicin 12 hourly penicillin/ampicillin/cloxacillin (n = 31) | Nephrotoxicity | Low risk; computerised generator used | Low risk; sealed envelopes used | High risk; no blinding | Low risk; no loss to follow-up | Low risk § |
| **Krishnam L et al. (1997)** [49] RCT; India | 4 mg/kg gentamicin 24 hourly + ampicillin/cloxacillin/crystalline penicillin/ceftazidime (n = 9) | 2.5 mg/kg gentamicin 12 hourly + ampicillin/cloxacillin/crystalline penicillin/ceftazidime (n = 9) | Nephrotoxicity | Unclear; insufficient information in publication | Unclear; insufficient information in publication | High risk; no blinding | Low risk; no loss to follow-up | Low risk § |
| Study ID, design and location | Intervention | Comparison | Outcomes | Risk of bias |
|------------------------------|--------------|------------|----------|--------------|
| Lundergan FS et al. (1999) [51]† | 5 mg/kg gentamicin loading dose then 4 mg/kg 24 hourly (term neonates), 2.5 mg/kg 24 hourly (all others) + ampicillin/additional antimicrobial (n = 64) | Historic cohort, gentamicin 2.5 mg/kg 24 hourly (weight <2000 g), 5 mg/kg 12 hourly (weight >2000 g) no loading doses (n = 57) | Nephrotoxicity and ototoxicity | High risk; treatment initiated at discretion of clinician, historical cohort |
| Mercado CK et al. (2004) [45]† RCT; USA | 4–5 mg/kg gentamicin 48 hourly + ampicillin (n = 19) | 2–2.5 mg/kg gentamicin twice daily + ampicillin (n = 21) | Nephrotoxicity and ototoxicity | Low risk; insufficient information in publication |
| Rastogi et al. (2002) [42]† RCT; USA | 48-h gentamicin dosing schedule + ampicillin (n = 30) | 24-h gentamicin dosing schedule + ampicillin (n = 28) | Nephrotoxicity and ototoxicity | High risk; list of random numbers used |
| Wiese G (1988) [50] RCT; Germany | 5 mg/kg gentamicin daily in 2 doses + azlocillin (n = 25) | 5 mg/kg gentamicin daily in 2 doses + ceftriaxone (n = 24) | Nephrotoxicity | Unclear; insufficient information in publication |

†Included in meta-analysis.
‡Unclear if additional antibiotic used, not specified in publication.
§Outcomes specified in objectives assessed and reported.
Table 2: Studies of gentamicin toxicity in hospitalised neonates assessed by adapted GRADE evidence profile

| Quality assessment | Summary of findings |
|--------------------|---------------------|
| Number of studies  | Hearing test/vestibular function test/definition of nephrotoxicity | Events in intervention group (total in group at end of study) | Events in comparison group (total in group at end of study) | Overall quality of evidence |
| (Design) Limitations | To population of interest | To intervention of interest | Study ID | |
| Generalisability | | | |
| | | | Agarwal (2002) [43]† | Natus ALGO screen | 0 (20) | 0 (21) | Low |
| | | | Finitzo-Hieber (1979) [52] | Year 1 – Denver development test; year 2 – behavioural response audiometry, visual reinforcement audiometry; year 3 – audiometry, impedance, vestibular assessment; year 4 – Illinois Test of psycholinguistic abilities, Beery test of visual motor Integration, Peabody picture vocabulary test, | 8 (59) | Kanamycin group: 3 (59) Control (no treatment) group: 5 (44) |
| | | | | Auditory toxicity defined as hearing loss detected by validated hearing test: | | |
| Auditory toxicity defined as hearing loss detected by validated hearing test: | | | Ishtarayounen (1982) [44] | Behavioural screen, ABR or both | 0 (20) | 0 (30) |
| | | | Lundergan (1999) [51]† | Natus ALGO screen | 2 (64) | 1 (57) |
| | | | Mercado (2004) [45]† | Natus ALGO 2 screen, follow-up ABR if abnormal | 2 (19) | 1 (21) |
| | | | Rastogi (2002) [42]† | Natus ALGO screen, follow-up ABR if abnormal | 0 (30) | 0 (28) |
| | | | Finitzo-Hieber (1979) [52] | Barany Rotational test | 1 (59) | Kanamycin group: 0 (59) Control (no treatment) group: 0 (44) |
| | | | | Vestibular toxicity defined as vestibular dysfunction detected by a validated vestibular function test: | | |
| vestibular toxicity defined as vestibular dysfunction detected by a validated vestibular function test: | | | Finitzo-Hieber (1979) [52] | Barany Rotational test | 1 (59) | Kanamycin group: 0 (59) Control (no treatment) group: 0 (44) |
| | | | | Vestibular toxicity defined as vestibular dysfunction detected by a validated vestibular function test: | | |
| Study ID | Hearing test/vestibular function test/definition of nephrotoxicity | Events in intervention group (total in group at end of study) | Events in comparison group (total in group at end of study) | Overall quality of evidence |
|----------|---------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------------------------|---------------------------|
| Adelman (1987) [46] Increase in SCr ≥ 0.3 mg/dl | 26% (38) | 12% (36) | Moderate |
| Agarwal (2002) [43]† Increase in SCr of 1 mg/dl or 0.5 mg/dl increase | Unclear (20) | Unclear (30)‡ |
| Chotigeat (2001) [47]† Increase in SCr (threshold not specified) | 0 (27) | 1 (27) |
| Itsarayoungyen (1982) [44] Increase in SCr (threshold not specified) | 0 (27) | 0 (27) |
| Kosalaraksa (2004) [48]† Increase in SCr (threshold not specified) | 0 (33) | 0 (31) |
| Krishnan (1997) [49]† Increase in SCr (threshold not specified) | 0 (9) | 0 (9) |
| Lundergan (1999) [51]† Increase in SCr by 0.5 mg/dl | 27% (64) | 26% (57) |
| Mercado (2004) [45]† ‘Normal’ SCr defined as level < 1 mg/dl | 0 (19) | 0 (21) |
| Rastogi (2002) [42]† Increase in SCr by 0.5 mg/dl | 0 (30) | 0 (28) |
| Wiese (1988) [50]† Increase in SCr (threshold not specified) | 0 (23) | 0 (22) |

Nephrotoxicity defined as increase in serum creatinine (SCr) as per thresholds specified in each individual study:

- No serious limitations
- Difficult to assess due to heterogeneous case definitions
- Serious imprecision (small sample sizes, few events)
- Serious indirectness (8 trials comparing different gentamicin dosing regimens)
- Yes

To population of interest

To intervention of interest

Hospitalised neonates

RCT, Randomised controlled trial; ABR, Auditory brainstem responses.

†Gentamicin administered to both intervention and comparison groups.

‡No differences in SCr between the two groups, unclear if nephrotoxic events occurred as not specified in publication.
of nephrotoxicity in neonates (or acute kidney injury) is needed, but this is in part hampered by difficulties in interpreting tests. New biomarkers to detect neonatal renal impairment are being investigated, but serum creatinine (SCr) is currently the gold standard test [34–36]. However, levels in the first 72 h of life can reflect the maternal SCr, and in fact, half of all neonatal renal function can be lost before changes in SCr are noted [35].

The limitations in the data in this review are all in the direction of underestimation of the true incidence of neonatal gentamicin toxicity. In eight studies, gentamicin was administered to both intervention and comparison groups [42, 43, 45, 47–51]. All trials were conducted in hospitalised neonates, where experienced clinicians, therapeutic drug monitoring, neonatal intensive care facilities and routine blood monitoring were available. This limits the generalisability of the data, as this standard of care is not universally accessible even in upper middle-income countries such as Thailand and without this care, the likelihood of toxicity is increased. [47, 48, 56, 57] If outpatient management is implemented at scale in LMICs, sick, preterm neonates with undetected impaired renal function will be at much higher risk of toxicity.

Although there are significant data limitations, as described previously, the importance of prevention of auditory toxicity and early identification of infants with hearing impairment cannot be overstated. Hearing loss is a leading cause of moderate and severe disability worldwide [58]. Children with hearing impairment in LMICs are more likely to be marginalised and subject to physical abuse [59]. Additionally, significant hearing loss increases risk of poor academic performance due to hindered speech and language development [60].

**Programmatic implications**

Where hospital treatment of PSBI is not accessible or feasible, outpatient management with antibiotic injections is associated with reduced neonatal mortality, especially in high burden settings [61]. Decisions on changes to future case management guidelines should include consideration of the potential for toxicity associated with treatment as well as changes in resistance patterns. Alternatives include cephalosporins, particularly for neonates at increased risk of toxicity (preterm, low birth weight or jaundiced). Whilst therapeutic drug monitoring may not be feasible in all healthcare facilities where treatment
is provided, monitoring should be undertaken where resources are more readily available, in larger hospitals. Additionally, systems should be put in place to ensure that dosing errors are avoided [62, 63].

Implementation of widespread neonatal hearing screening in LMICs would be challenging with high costs of equipment and the deficit of skilled healthcare workers. Targeted hearing screening of high-risk neonates, such as those exposed to gentamicin, may be possible in the short to medium term. If supported by treatment, this would confer long-term benefit to the infants as speech and language development is improved with early identification of hearing impairment and appropriate rehabilitation [64].

Recommendations for further research

There is a need for well-designed prospective cohort studies assessing the frequency of toxic levels of gentamicin using current standard of care in LMICs. In addition, a multicentre, well-designed, adequately powered randomised controlled trial evaluating outcomes after either first-line treatment with aminoglycosides or a third generation cephalosporin for neonatal PSBI is needed.

Innovative approaches to assessing gentamicin levels and to measuring ototoxicity are also key areas for research, possibly through public–private partnerships. A possible method to facilitate serum gentamicin level measurement is microsampling, using filter paper to collect blood from finger or heel pricks. Microsamples on filter paper are simple to collect and transport. Further research is required to determine agreement with results from larger volume samples [65, 66].

In the meantime, when workers at any level of the health system are using gentamicin for neonatal PSBI, [61,67] investments are urgently required to improve coverage data [68] and for implementation research to improve accuracy of prescribing and administration particularly for preterm, sick neonates where overdoses will do the most damage.

Conclusion

The lack of data on gentamicin toxicity risk in neonates, for ototoxicity and nephrotoxicity, is striking, particularly in LMICs where the disease burden, and need for antibiotic treatment is greatest. Particularly with expansion of outpatient management in settings where access to hospital-based care is limited, more attention and further research is essential to ensure that much needed scale-up to ensure access to treatment does not result in also doing harm.

Funding

No specific funding was received for this study.

References

1. Lawn JE, Blencowe H, Oza S et al. Every newborn: progress, priorities, and potential beyond survival. Lancet 2014: 384: 189–205.
2. Seale AC, Blencowe H, Manu AA et al. Estimates of possible severe bacterial infection in neonates in sub-Saharan Africa, south Asia, and Latin America for 2012: a systematic review and meta-analysis. Lancet Infect Dis 2014: 14: 731–741.
3. World Health Organization. Integrated Management of Childhood Illness Chart Booklet. World Health Organization, editor. World Health Organization: Geneva, Switzerland, 2014.
4. Arifeen SE, Hoque DME, Akter T et al. Effect of the integrated management of childhood illness strategy on childhood mortality and nutrition in a rural area in Bangladesh: a cluster randomised trial. Lancet 2009: 374: 393–403.
5. World Health Organization. Pocket Book of Hospital Care for Children (2nd edn). World Health Organization, editor. World Health Organization: Geneva, Switzerland, 2013.
6. United Nations Commission on Life-Saving Commodities. United Nations Commission on Life Saving Commodities. 2015. (Available from: http://www.everywomaneverychild.org/resources/un-commission-on-life-saving-commodities.)
7. Nair H, Campbell H. Community management of neonatal infections. Lancet 2015: 385: 1706–1709.
8. Mulholland K, Carlin JB, Duke T, Weber M. The challenges of trials of antibiotics for pneumonia in low-income countries. Lancet Respir Med 2014: 2: 952–954.
9. Karim AM, Admassu K, Schellenberg J et al. Effect of Ethiopia’s health extension program on maternal and newborn health care practices in 101 rural districts; a dose-response study. PLoS ONE 2013: 8: e65160.
10. English M, Mohammed S, Ross A et al. A randomised, controlled trial of once daily and multi-dose daily gentamicin in young Kenyan infants. Arch Dis Child 2004: 89: 665–669.
11. Schultze RG, Winters RE, Kauffman H. Possible nephrotoxicity of gentamicin. J Infect Dis 1971: 124(Suppl): S145–S147.
12. Jackson GG, Arcieri G. Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. J Infect Dis 1971: 124(Suppl): S130–S137.
13. Riff LJ, Jackson GG. Pharmacology of gentamicin in man. J Infect Dis 1971: 124(Suppl): S98–S105.
14. McGlone A, Cranswick N. Evidence behind the WHO guidelines: hospital care for children: what is the evidence of safety of gentamicin use in children? J Trop Pediatr 2008: 54: 291–293.
15. Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011: 2011: 937861.
16. Selimoglu E. Aminoglycoside-induced ototoxicity. *Curr Pharm Des* 2007; 13: 119–126.
17. Cristobal R, Oghalai JS. Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology. *Arch Dis Child Fetal Neonatal Ed* 2008; 93: F462–F468.
18. Andreoli SP. Acute renal failure in the newborn. *Semin Perinatol* 2004; 28: 112–123.
19. Mathur NB, Agarwal HS, Maria A. Acute renal failure in neonatal sepsis. *Indian J Pediatr* 2006; 73: 499–502.
20. Agra PI, Tarcan A, Baskin E, Cengiz N, Gürakan B, Saatci U. Acute renal failure in the neonatal period. *Ren Fail* 2004; 26: 305–309.
21. Scale AC, Blencowe H, Zaidi A et al. Neonatal severe bacterial infection impairment estimates in South Asia, sub-Saharan Africa, and Latin America for 2010. *Pediatr Res* 2013; 74(Suppl 1): 73–85.
22. Robertson CMT, Tyebkhan JM, Hagler ME, Cheung P-Y, Peliowski A, Etches PC. Late-onset, progressive sensorineural hearing loss after severe neonatal respiratory failure. *Otol Neurotol* 2002; 23: 353–356.
23. Li H & Steyger PS. Synergistic ototoxicity due to noise exposure and aminoglycoside antibiotics. *Noise Health* 2009: 11: 26–32.
24. Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. *Am N Y Acad Sci* 1999: 884: 15–18.
25. Dahlgren JG, Anderson ET, Hewitt WL. Gentamicin blood levels: a guide to nephrotoxicity. *Antimicrob Agents Chemother* 1975: 8: 58–62.
26. Mulhall A, de Louvois J, Hurley R. Incidence of potentially toxic concentrations of gentamicin in the neonate. *Arch Dis Child* 1983: 58: 897–900.
27. McCormack JP, Jewesson PJ. A critical reevaluation of the “therapeutic range” of aminoglycosides. *Clin Infect Dis* 1992: 14: 320–339.
28. Assael BM, Gianni V, Marini A, Peneff P, Sereni F. Gentamicin dosage in preterm and term neonates. *Arch Dis Child* 1977: 52: 883–886.
29. Darmstadt GL, Miller-Bell M, Batra M, Law P, Law K. Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries. *J Health Popul Nutr* 2008: 26: 163–182.
30. Binner-Glindzicz M, Pembrey M, Duncan A et al. Prevalence of mitochondrial 1355A→G mutation in European children. *N Engl J Med* 2009: 360: 640–642.
31. Hu DN, Qui WQ, Wu BT et al. Genetic aspects of antibiotic induced deafness: mitochondrial inheritance. *J Med Genet* 1991: 28: 79–83.
32. Hutchin T, Haworth I, Higashi K et al. A molecular basis for human hypersensitivity to aminoglycoside antibiotics. *Nucleic Acids Res* 1993; 21: 4174–4179.
33. Young Infants Clinical Signs Study Group. Young children that predict severe illness in children under age 2 months: a multicentre study. *Lancet* 2008: 371: 135–142.
34. McWilliam SJ, Antoine DJ, Sabbisetti V et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. *PLoS ONE* 2012: 7: e43809.
35. Libório AB, Branco KMPC & de Torres Melo Bezerra C. Acute kidney injury in neonates: from urine output to new biomarkers. *Biomed Res Int* 2014: 2014: 601568.
36. Bagshaw SM, Langenberg C, Haase M, Wan L, May CN, Bellomo R. Urinary biomarkers in septic acute kidney injury. *Intensive Care Med* 2007: 33: 1285–1296.
37. Higgins J, Altman D & Sterne J. Assessing Risk of Bias in Included Studies. In: Higgins JPT & Green S (eds). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*. [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
38. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004: 328: 1490.
39. Omer SB, Colley DG, Hurdle JF, Weiss SJ. The global burden of disease study. *JAMA* 2004: 291: 1588–1597.
40. Blencowe H, Yuen T, Lee ACC et al. Estimates of neonatal morbidities and disabilities at regional and global levels for 2008: introduction, methods overview, and relevant findings from the Global Burden of Disease study. *Pediatr Res* 2013: 74(Suppl 1): 4–16.
41. Blencowe H, Von T, Lee ACC et al. Estimates of neonatal morbidities and disabilities at regional and global levels for 2010: introduction, methods overview, and relevant findings from the Global Burden of Disease study. *Pediatr Res* 2013: 74(Suppl 1): 4–16.
42. Rastogi A, Agarwal G, Pyle S, Pildes RS. Comparison of two gentamicin dosing schedules in very low birth weight infants. *Pediatr Infect Dis J* 2002: 21: 234–240.
43. Agarwal G, Rastogi A, Pyle S, Wilks A, Pildes RS. Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants > or = 2500 g. *J Perinatol* 2002: 22: 268–274.
44. Itskhoy Siff L, Schaull V, Hamilton L, Otembria J, Vidyasagar D. Tobramycin and gentamicin are equally safe for neonates: results of a double-blind randomized trial with quantitative assessment of renal function. *Pediatr Pharmacol (New York)* 1982: 2: 143–155.
45. Mercado MCK, Brodsky NL, McGuire MK, Hurt H. Extended interval dosing of gentamicin in preterm infants. *Am J Perinatol* 2004: 21: 73–77.
46. Adelman RD, Wirth F, Rubio T. A controlled study of the nephrotoxicity of mezlocillin and gentamicin plus ampicillin in the neonate. *Pediatr Res* 1987: 11(6 Pt 1): 888–893.
47. Chotigeat U, Narongsanti A, Ayudhya DP. Gentamicin in neonatal infection: once versus twice daily dosage. *J Med Assoc Thai* 2001: 84: 1109–1115.
48. Kosalaraksa P, Janthep P, Jirapradittha J, Taksaphan S, Kiatchoosakun P. Once versus twice daily dose of gentamicin therapy in Thai neonates. *J Med Assoc Thai* 2004: 87: 372–376.
49. Krishnan L, George SA. Gentamicin therapy in preterm: a comparison of two dosage regimens. *Indian Pediatr* 1997: 34: 1075–1080.
comparison of efficacy and tolerability. *Chemotherapy* 1988: 34: 158–163.

51. Lundergan FS, Glasscock GF, Kim EH, Cohen RS. Once-daily gentamicin dosing in newborn infants. *Pediatrics* 1999: 103(6 Pt 1): 1228–1234.

52. Finitzo-Hieber T, McCracken GH, Roese RJ, Allen DA, Chrane DF, Morrow J. Ototoxicity in neonates treated with gentamicin and kanamycin: results of a four-year controlled follow-up study. *Pediatrics* 1979: 63: 443–450.

53. Herbert HK, Lee ACC, Chandran A, Rudan I, Baqui AH. Care seeking for neonatal illness in low- and middle-income countries: a systematic review. *PLoS Med* 2012: 9: e1001183.

54. Althabe F, Belizán JM, McClure EM et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. *Lancet* 2015: 385: 629–639.

55. Fife TD, Tusa RJ, Furman JM et al. Assessment: vestibular testing techniques in adults and children: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2000: 55: 1431–1441.

56. Simen-Kapeu A, Scale A C, Wall S et al. Management of neonatal infections: a multi-country analysis of health system bottlenecks and potential solutions. *BMC Pregnancy Childbirth* 2015:15(S2): S6.

57. Balabanova D, McKee M & Mills A. Good Health at Low Cost 25 Years On. *What Makes a Successful Health System?* London School of Hygiene and Tropical Medicine: London, 2011.

58. World Health Organization. *World Report on Disability.* World Health Organization: Geneva, 2011.

59. UNICEF, University of Wisconsin. *Monitoring Child Disability in Developing Countries: Results from the Multiple Indicator Cluster Surveys.* UNICEF: New York, 2008.

60. World Health Organization. *Newborn and Infant Screening.* Current issues and guiding principles for action: Geneva, 2010.

61. African Neonatal Sepsis Trial group, Tshefu A, Lokangaka A et al. Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial. *Lancet* 2015: 385: 1758–1766.

62. Aluvaala J, Nyamai R, Were F et al. Assessment of neonatal care in clinical training facilities in Kenya. *Arch Dis Child* 2015: 100: 42–47.

63. NHS National Patient Safety Agency. *Safer use of Intravenous Gentamicin for Neonates.* London: NHS National Patient Safety Agency, 2010.

64. McPherson B. Newborn hearing screening in developing countries: needs & new directions. *Indian J Med Res* 2012: 135: 152–153.

65. Tawa R, Matsunaga H, Fujimoto T. High-performance liquid chromatographic analysis of aminoglycoside antibiotics. *J Chromatogr A* 1998: 812: 141–150.

66. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. *J Nutr* 2001: 131: 1631S–1636S.

67. World Health Organization. Managing possible serious bacterial infection in young infants when referral is not feasible: guidelines 2015. [http://www.who.int/maternal_child_adolescent/documents/bacterial-infectioninfants/en/][16 September 2015]

68. Moxon S G, Ruysen H, Kerber K et al. Count every newborn; a measurement improvement roadmap for coverage data. *BMC Pregnancy Childbirth* 2015: 15(S2): S8.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

Table S1. Study identifiers and context.
Table S2. Study Design and Methodology.
Table S3. Study Limitations.
Table S4. Participants.
Table S5. Intervention.
Table S6. Ototoxicity.
Table S7. Nephrotoxicity and Dosing errors.

**Corresponding Author** Anna C. Scale, Department of Infectious Diseases Informatics, UCL Institute for Health Informatics, University College London, Farr Institute, 222 Euston Road, London NW1 2DA, UK. E-mail: a.scale@ucl.ac.uk

© 2015 John Wiley & Sons Ltd